Vertex Pharmaceuticals Incorporated vs Amphastar Pharmaceuticals, Inc.: A Gross Profit Performance Breakdown

Vertex vs. Amphastar: A Decade of Gross Profit Growth

__timestampAmphastar Pharmaceuticals, Inc.Vertex Pharmaceuticals Incorporated
Wednesday, January 1, 201451256000519428000
Thursday, January 1, 201577347000906794000
Friday, January 1, 20161041890001491717000
Sunday, January 1, 2017907950002213533000
Monday, January 1, 20181069850002638058000
Tuesday, January 1, 20191319230003615063000
Wednesday, January 1, 20201433400005469383000
Friday, January 1, 20211997390006670200000
Saturday, January 1, 20222488600007850400000
Sunday, January 1, 20233511210008607000000
Monday, January 1, 20249489600000
Loading chart...

Unleashing insights

A Tale of Two Pharmaceutical Giants: Vertex vs. Amphastar

In the competitive landscape of pharmaceuticals, Vertex Pharmaceuticals Incorporated and Amphastar Pharmaceuticals, Inc. have showcased contrasting trajectories in gross profit over the past decade. From 2014 to 2023, Vertex's gross profit surged by an impressive 1,557%, reaching approximately $8.6 billion. This growth underscores Vertex's strategic prowess in the biotech sector, particularly in the development of innovative therapies.

Conversely, Amphastar's journey, while more modest, reflects steady progress. Their gross profit increased by 585% over the same period, peaking at around $351 million in 2023. This growth highlights Amphastar's resilience and adaptability in a highly competitive market.

The data reveals a compelling narrative of growth and innovation, with Vertex leading the charge in biotech advancements, while Amphastar steadily carves its niche. As these companies continue to evolve, their financial trajectories offer valuable insights into the dynamic world of pharmaceuticals.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025